Ligand Pharma (LGND) Misses Q1 EPS by 6c, Miss on Revenues; Light FY17 Guidance

Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.57, $0.06 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $29.6 million versus the consensus estimate of $31.24 million.

GUIDANCE:

Ligand Pharma sees FY2017 EPS of $2.70, versus the consensus of $2.71. Ligand Pharma sees FY2017 revenue of $130 million, versus the consensus of $133.9 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• Citi upgrades C.H. Robinson to Buy with $185 target, Opens 90-Day upside catalyst watch
• Roth/MKM Downgrades eGain Corporation (EGAN) to Neutral